Viscira®, a leading provider of interactive, new-media communication solutions and software products for the life sciences industry, today announced the opening of a new office in London. This destination will serve as a launching point for the company to expand its business in the top five European markets (France, Germany, Italy, Spain, and the United Kingdom) and beyond.
This move represents a logical next step given Viscira’s rapid growth and its current base of major global life science clients, including Roche, Bristol-Myers Squibb, Novartis and AbbVie. It also follows the increasing use of digital technology and channels by European pharmaceutical companies.
According to a recent report issued by Cegedim Strategic Data, European pharmaceutical companies, including those from the UK, Germany, France, Spain and Italy, raised their aggregate spending on digital channels by almost 40% from 2011 to 2012.1 This growth is expected to continue.
“Our expansion in Europe is a major step for the company. Although we have already been doing a meaningful amount of work in the EU, this move will enable us to better serve our clients there and help to further build our business,” explained Dave Gulezian, President & CEO of Viscira. “More and more of the work we are doing for our clients includes a global component and we only expect this need to grow.”
Nicole Tulli, Director of Global Business Development, will be relocating to London to spearhead Viscira’s efforts in the EU. Nicole has been with the company since 2010 and has helped to develop innovative digital solutions for top-tier pharmaceutical companies such as Bristol-Myers Squibb, Teva, and AstraZeneca.
“I am very excited to have this opportunity to lead Viscira’s expansion into the European market. I’m confident that our unique and sophisticated digital solutions, along with our ability to develop high-impact digital strategies, will enable us to provide significant value to European life science clients,” Tulli commented.